MX2013006420A - Derivados de aminotriazol hidrolixado como agonistas del receptor de alx. - Google Patents

Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.

Info

Publication number
MX2013006420A
MX2013006420A MX2013006420A MX2013006420A MX2013006420A MX 2013006420 A MX2013006420 A MX 2013006420A MX 2013006420 A MX2013006420 A MX 2013006420A MX 2013006420 A MX2013006420 A MX 2013006420A MX 2013006420 A MX2013006420 A MX 2013006420A
Authority
MX
Mexico
Prior art keywords
receptor agonists
aminotriazole derivatives
alx receptor
hydroxylated aminotriazole
hydroxylated
Prior art date
Application number
MX2013006420A
Other languages
English (en)
Inventor
Daniel Bur
Olivier Corminboeuf
Sylvaine Cren
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2013006420A publication Critical patent/MX2013006420A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a derivados de aminotriazol hidroxilado de fórmula (I), donde Q, R1, R2, R3 y R4 son como se define en la descripción, a su preparación y a su uso como compuestos farmacéuticamente activos.
MX2013006420A 2010-12-07 2011-12-06 Derivados de aminotriazol hidrolixado como agonistas del receptor de alx. MX2013006420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2010055614 2010-12-07
PCT/IB2011/055492 WO2012077051A1 (en) 2010-12-07 2011-12-06 Hydroxylated aminotriazole derivatives as alx receptor agonists

Publications (1)

Publication Number Publication Date
MX2013006420A true MX2013006420A (es) 2013-07-29

Family

ID=45446117

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006420A MX2013006420A (es) 2010-12-07 2011-12-06 Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.

Country Status (14)

Country Link
US (1) US9346793B2 (es)
EP (1) EP2648724B1 (es)
JP (1) JP5923108B2 (es)
KR (1) KR101847672B1 (es)
CN (1) CN103249413B (es)
AR (1) AR084172A1 (es)
AU (1) AU2011340103A1 (es)
BR (1) BR112013014035A2 (es)
CA (1) CA2816406C (es)
ES (1) ES2604135T3 (es)
MX (1) MX2013006420A (es)
RU (1) RU2013130878A (es)
TW (1) TW201305150A (es)
WO (1) WO2012077051A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640699B1 (en) 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Bridged spiro[2,4]heptane ester derivatives
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
US9284288B2 (en) 2012-05-16 2016-03-15 Actelion Pharmaceuticals Ltd. 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
RU2016105310A (ru) 2013-07-18 2017-08-23 Актелион Фармасьютиклз Лтд Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
MA39069B1 (fr) 2013-11-28 2018-11-30 Kyorin Pharmaceutical Co Ltd Dérivé d'urée ou sel pharmacologiquement acceptable de celui-ci
EP3331884B1 (en) 2015-05-27 2020-06-17 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
ES2791340T3 (es) 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
PE20210046A1 (es) 2018-03-05 2021-01-08 Bristol Myers Squibb Co Agonistas de fenilpirrolidinona del receptor 2 de formil peptido

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
KR20030030029A (ko) 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
WO2003082314A2 (en) 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
CA2544983A1 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
AU2006312083A1 (en) 2005-11-03 2007-05-18 Merck Sharp & Dohme Corp. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
CA2982520A1 (en) 2007-08-21 2009-02-26 Senomyx, Inc. Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
AR069650A1 (es) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
RU2492167C2 (ru) 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные аминотриазола в качестве агонистов alх
JP5510945B2 (ja) 2009-05-18 2014-06-04 アクテリオン ファーマシューティカルズ リミテッド Ａｌｘ受容体及び／又はｆｐｒｌ２アゴニストとしての架橋スピロ［２．４］ヘプタン誘導体
EP2440555B1 (en) * 2009-06-09 2016-05-18 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives
CN102803237B (zh) * 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
EP2640699B1 (en) 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Bridged spiro[2,4]heptane ester derivatives
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
US9284288B2 (en) 2012-05-16 2016-03-15 Actelion Pharmaceuticals Ltd. 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists

Also Published As

Publication number Publication date
RU2013130878A (ru) 2015-01-20
US9346793B2 (en) 2016-05-24
ES2604135T3 (es) 2017-03-03
WO2012077051A1 (en) 2012-06-14
EP2648724A1 (en) 2013-10-16
BR112013014035A2 (pt) 2016-09-13
CA2816406C (en) 2019-02-26
TW201305150A (zh) 2013-02-01
CN103249413A (zh) 2013-08-14
JP2013544879A (ja) 2013-12-19
US20130267569A1 (en) 2013-10-10
JP5923108B2 (ja) 2016-05-24
AU2011340103A1 (en) 2013-07-25
KR20130133239A (ko) 2013-12-06
KR101847672B1 (ko) 2018-04-10
EP2648724B1 (en) 2016-09-21
CA2816406A1 (en) 2012-06-14
AR084172A1 (es) 2013-04-24
CN103249413B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MY153985A (en) Aminotriazole derivatives as alx agonists
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
MX2011012739A (es) Derivados fluorados de aminotriazol.
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
MY153921A (en) Aminopyrazole derivatives
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX2010004576A (es) Derivados de pirimidina novedosos.
MX2012000414A (es) Derivados piridin-4-ilo.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
UA108105C2 (ru) Азотсодержащие гетероарильные соединения
PH12015501339A1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
IN2012DN03182A (es)
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.
MX346248B (es) Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2.
IN2015DN01119A (es)
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
PH12014502465A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
PH12014501415A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
MX337320B (es) Análogos halogenados de agentes anti-fibroticos.
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal